Sept 7 (Reuters) - Kalytera Therapeutics Inc KALY.V
* Kalytera receives IRB approval for proposed phase 2 study evaluating CBD in the prevention of graft versus host disease
* Kalytera Therapeutics Inc - Kalytera has received approval from IRB at beilinson to commence phase 2 study